title: Response to treatment series: part 2, tumor response assessment--using new and conventional criteria.
abstract: OBJECTIVE
  Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy.
  
  
  CONCLUSIONS
  Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.
authors.affiliation: Department of Radiology, Northwestern Memorial Hospital, Northwestern University-Feinberg School of Medicine, Chicago, IL 60611, USA. v-yaghmai@northwestern.edu
authors.forename: Vahid
authors.initials: V
authors.lastname: Yaghmai
authors.forename: Frank H
authors.initials: FH
authors.lastname: Miller
authors.forename: Pedram
authors.initials: P
authors.lastname: Rezai
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
authors.forename: Riad
authors.initials: R
authors.lastname: Salem
mesh_terms: D006801:Humans; D057054:Molecular Imaging / Q000639:trends*; D015336:Molecular Probe Techniques / Q000639:trends*; D009369:Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D016896:Treatment Outcome